Table 3.

Demographic and clinical characteristics of MOG-IgG patients

MOG-IgG patients, n	3
Age, years (SD)	39.56 (22.84)
Female, n (%)	3 (100)
Disease duration, years (SD)	7.50 (1.98)
EDSS pre-RTX start, (range)	1.0 (0–4)
EDSS after RTX start (range)	1.0 (0–4)
ARR 1 year before RTX start (SD)	2.00 (1.73)
ARR after RTX start (SD)	0.13 (0.13)
Relapse free time, years (SD)	3.97 (3.09)
Previous treatments, n (range)	0 (0–1)
Previous immunosuppressive treatment history, n (%)	1 (33.33)
Naïve	2
Azathioprine	1
Follow-up time from RTX start, years (range)	5.17 (3.67–7.43)

Age, disease duration, relapse free time, and ARR are expressed as mean; previous treatments, EDSS, and follow-up time are expressed as median

MOG-IgG myelin oligodendrocyte glycoprotein, EDSS Expanded Disability Status Scale, ARR annualized relapse rate, RTX Rituximab